AG
TBPH icon

Advisor Group’s Theravance Biopharma TBPH Stock Holding History

Advisor Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Hold
10
– – ﹤0.01% 5439
2019
Q3 		$0 Hold
10
– – ﹤0.01% 5414
2019
Q2 		$0 Hold
10
– – ﹤0.01% 5353
2019
Q1 		$0 Hold
10
– – ﹤0.01% 5322
2018
Q4 		$0 Hold
10
– – ﹤0.01% 5228
2018
Q3 		$0 Buy
+10
New +$273 ﹤0.01% 5212

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LFS
Link Fund Solutions London, United Kingdom $157M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Advisor Group's TBPH Position: Q4 2019 in Review

Advisor Group held its Theravance Biopharma (TBPH) position steady in Q4 2019 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5439.

Advisor Group first reported a position in TBPH in Q3 2018 and has held it in 6 quarters since. 108 funds tracked by Wall St. Rank hold TBPH as of Q4 2019.

  • Advisor Group held 10 shares of Theravance Biopharma worth $0 as of Q4 2019.
  • Advisor Group left its Theravance Biopharma share count unchanged in Q4 2019.
  • Theravance Biopharma made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5439 holding.
  • Advisor Group first reported a position in Theravance Biopharma in Q3 2018 and has held it in 6 quarters since.
  • 108 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.